For: | Chen P, Yu M, Zhang JL, Chen WY, Zhu L, Song Y, Jiang CY, Zhang S. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. World J Clin Cases 2020; 8(13): 2876-2884 [PMID: 32742998 DOI: 10.12998/wjcc.v8.i13.2876] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v8/i13/2876.htm |
Number | Citing Articles |
1 |
Lei Wang, Yingyu Huang, Xin Sun. Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1362160
|
2 |
|
3 |
Chunsen Wang, Xiang Yuan, Jianxin Xue. Targeted therapy for rare lung cancers: Status, challenges, and prospects. Molecular Therapy 2023; 31(7): 1960 doi: 10.1016/j.ymthe.2023.05.007
|
4 |
Yue Zheng, Yang Fu, Qin Zhong, Rong Deng, Yu Zhang. The treatment of advanced pulmonary sarcomatoid carcinoma. Future Oncology 2022; 18(6): 727 doi: 10.2217/fon-2021-1071
|
5 |
Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Patrice Desmeules, Rosalyn A. Juergens, Natasha B. Leighl, Brandon S. Sheffield, Paul F. Wheatley-Price, Barbara L. Melosky. Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology 2021; 28(6): 4552 doi: 10.3390/curroncol28060386
|
6 |
Yu Wang, Lin Yang, Jianyang Wang, Lin Gui, Wei Li, Zhiqiang Liu, Xiangyu Ma, Yin Yang, Luhua Wang, Nan Bi. Case Report: First Case of Consolidation Immunotherapy After Definitive Chemoradiotherapy in Mediastinal Lymph Node Metastatic Sarcomatoid Carcinoma. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.788856
|